000893096 001__ 893096
000893096 005__ 20211130111106.0
000893096 0247_ $$2doi$$a10.1002/mds.28674
000893096 0247_ $$2ISSN$$a0885-3185
000893096 0247_ $$2ISSN$$a1531-8257
000893096 0247_ $$2Handle$$a2128/28785
000893096 0247_ $$2altmetric$$aaltmetric:107241471
000893096 0247_ $$2pmid$$apmid:34096652
000893096 0247_ $$2WOS$$aWOS:000658342200001
000893096 037__ $$aFZJ-2021-02555
000893096 082__ $$a610
000893096 1001_ $$0P:(DE-Juel1)184882$$aSeger, Aline$$b0
000893096 245__ $$aPutaminal y ‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease
000893096 260__ $$aNew York, NY$$bWiley$$c2021
000893096 3367_ $$2DRIVER$$aarticle
000893096 3367_ $$2DataCite$$aOutput Types/Journal article
000893096 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634192128_4066
000893096 3367_ $$2BibTeX$$aARTICLE
000893096 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000893096 3367_ $$00$$2EndNote$$aJournal Article
000893096 520__ $$aBackgroundMotor response to dopaminergic therapy is a characteristic of patients with Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment response is uncertain.ObjectivesThe aim of this study is to determine whether putaminal y-aminobutyric acid (GABA) levels are associated with dopaminergic motor response.MethodsWe assessed putaminal GABA levels in 19 PD patients and 13 healthy controls (HCs) utilizing ultra-high field proton magnetic resonance spectroscopy. Motor performance was evaluated using the Movement Disorder Society—Unified Parkinson's Disease Rating Scale, Part III, in the ON and OFF states. Statistical analysis comprised group comparisons, correlation analysis, and multiple linear regression.ResultsIn PD, GABA levels were significantly higher compared to HCs (1.50 ± 0.26 mM vs. 1.26 ± 0.31 mM, P = 0.022). Furthermore, GABA levels were independent predictors of absolute and relative dopaminergic treatment response.ConclusionsOur findings indicate that elevated putaminal GABA levels are associated with worse dopaminergic response in PD, emphasizing the essential role of nondopaminergic neurotransmitters in motor response. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
000893096 536__ $$0G:(DE-HGF)POF4-525$$a525 - Decoding Brain Organization and Dysfunction (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000893096 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000893096 7001_ $$0P:(DE-Juel1)138244$$aFarrher, Ezequiel$$b1
000893096 7001_ $$0P:(DE-Juel1)161350$$aDoppler, Christopher E. J.$$b2
000893096 7001_ $$0P:(DE-Juel1)178065$$aGogishvili, Ana$$b3
000893096 7001_ $$0P:(DE-Juel1)156200$$aWorthoff, Wieland A.$$b4
000893096 7001_ $$0P:(DE-Juel1)141877$$aFilss, Christian P.$$b5
000893096 7001_ $$0P:(DE-Juel1)131613$$aBarbe, Michael T.$$b6
000893096 7001_ $$0P:(DE-Juel1)188521$$aHoltbernd, Florian$$b7
000893096 7001_ $$0P:(DE-Juel1)131794$$aShah, N. Jon$$b8
000893096 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b9$$ufzj
000893096 7001_ $$0P:(DE-Juel1)179044$$aSommerauer, Michael$$b10$$eCorresponding author
000893096 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.28674$$gp. mds.28674$$n9$$p2187-2192$$tMovement disorders$$v36$$x1531-8257$$y2021
000893096 8564_ $$uhttps://juser.fz-juelich.de/record/893096/files/mds.28674.pdf$$yOpenAccess
000893096 909CO $$ooai:juser.fz-juelich.de:893096$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)184882$$aForschungszentrum Jülich$$b0$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)138244$$aForschungszentrum Jülich$$b1$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)161350$$aForschungszentrum Jülich$$b2$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)178065$$aForschungszentrum Jülich$$b3$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156200$$aForschungszentrum Jülich$$b4$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)141877$$aForschungszentrum Jülich$$b5$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)188521$$aForschungszentrum Jülich$$b7$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b8$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b9$$kFZJ
000893096 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)179044$$aForschungszentrum Jülich$$b10$$kFZJ
000893096 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000893096 9130_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000893096 9141_ $$y2021
000893096 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000893096 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000893096 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2019$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-30$$wger
000893096 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000893096 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2019$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-30
000893096 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-30$$wger
000893096 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000893096 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000893096 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x1
000893096 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x2
000893096 9201_ $$0I:(DE-Juel1)VDB1046$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x3
000893096 980__ $$ajournal
000893096 980__ $$aVDB
000893096 980__ $$aUNRESTRICTED
000893096 980__ $$aI:(DE-Juel1)INM-4-20090406
000893096 980__ $$aI:(DE-Juel1)INM-3-20090406
000893096 980__ $$aI:(DE-Juel1)INM-11-20170113
000893096 980__ $$aI:(DE-Juel1)VDB1046
000893096 9801_ $$aFullTexts